LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection.

Authors :: Bex, A.
Uzzo, R.
Karam, J.A.
Master, V.A.
Donskov, F.
Suárez, C.
Albiges, L.
Rini, B.I.
Tomita, Y.
Kann, A.
Procopio, G.
Massari, F.
Zibelman, M.
Antonyan, I.
Huseni, M.
Basu, D.
Ci, B.
Leung, W.
Khan, O.
Pal, S.K.
Source :: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1431-S1432. 2p.
Publication Year :: 2022

Full Text Access

Tools